Risiko for at udvikle neutraliserende antistoffer, er, selv ved langtids- behandling, lav, da aminosyrekæden er identisk med den for endogent humant calcitonin.
The risk of developing neutralising antibodies, even in the case of long-term therapy, is low because the amino acid sequence is identical to that of endogenous human calcitonin.